home / stock / avir / avir news

AVIR News and Press, Atea Pharmaceuticals Inc. From 11/02/23

Stock Information
Company Name: Atea Pharmaceuticals Inc.
Stock Symbol: AVIR
Market: NASDAQ
Website: ateapharma.com
Menu
AVIR AVIR Quote AVIR Short AVIR News AVIR Articles AVIR Message Board
Get AVIR Alerts

News, Short Squeeze, Breakout and More Instantly...
AVIR - Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at The Liv...
AVIR - Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confe...

AVIR - Atea Pharmaceuticals: Hoping Its COVID Efforts Are Still Relevant

2023-09-27 01:43:08 ET Summary Atea Pharmaceuticals is a small biotech company with a focus on developing antiviral therapeutics for viral infections. Their lead product candidate, AT-527, is currently in a Phase III study for the treatment of COVID-19 in high-risk patients. A...

AVIR - Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea mana...
AVIR - TWST, NSTG and VRNT are among after hour movers

2023-08-17 17:37:41 ET Gainers: EDAP  ( NASDAQ: EDAP ) +7% . Hyperfine ( HYPR ) +7% . Ross Stores ( ROST ) +6% . Verint Systems  ( VRNT ) +6% . NanoString Technologies ( NSTG ) +4% . Losers: VinFast Auto ...

AVIR - Atea downgraded at JPMorgan on shrinking COVID opportunity

2023-08-10 10:20:13 ET More on Atea Atea Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Atea Pharmaceuticals, Inc. ( AVIR ) Q2 2023 Earnings Call Transcript Atea rejects takeover offer from Tang Capital Partners Atea Pharmaceuticals ...

AVIR - Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Call Transcript

2023-08-08 22:04:10 ET Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Jonae Barnes – Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi – Chi...
AVIR - Atea Pharmaceuticals GAAP EPS of -$0.34 beats by $0.15

2023-08-08 17:49:56 ET Atea Pharmaceuticals press release ( NASDAQ: AVIR ): Q2 GAAP EPS of -$0.34 beats by $0.15 . Cash, Cash Equivalents and Marketable Securities: $608.1 million at June 30, 2023 compared to $646.7 million at December 31, 2022. ...

AVIR - Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment Enrollment continues in Phase...

AVIR - Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confe...
Previous 10 Next 10